We are live on ! Find out more
FCMI

Foresite Capital Management III Portfolio holdings

AUM $37.9M
1-Year Est. Return 6.87%
This Fund
S&P 500
This Quarter Est. Return
-2.59%
1 Year Est. Return
-6.87%
3 Year Est. Return
+444.07%
5 Year Est. Return
+547.28%
10 Year Est. Return
–
AUM
$262M
AUM Growth
-$43M
Cap. Flow
-$14.5M
Cap. Flow %
-5.52%
Top 10 Hldgs %
89.8%
Holding
18
New
–
Increased
3
Reduced
6
Closed
4

Top Buys

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$9.16M
2
BPMC
Blueprint Medicines
BPMC
+$7.93M
3
IMMU
Immunomedics Inc
IMMU
+$261K

Top Sells

Rank Stock Value
1
RCUS icon
Arcus Biosciences
RCUS
+$10.9M
2
ALDR
Alder Biopharmaceuticals
ALDR
+$6.27M
3
FBRX icon
Forte Biosciences
FBRX
+$3.79M
4
WVE icon
Wave Life Sciences
WVE
+$3.65M
5
REPL icon
Replimune Group
REPL
+$2.58M

Sector Composition

Rank Sector Weight
1 Healthcare 67.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AERI
1
DELISTED
Aerie Pharmaceuticals
AERI
$45.2M 17.25%
2,350,477
+400,000
+21% +$9.16M
ALDR
2
DELISTED
Alder Biopharmaceuticals
ALDR
$45.1M 17.24%
2,393,612
-548,518
-19% -$6.27M
BPMC
3
DELISTED
Blueprint Medicines
BPMC
$41.1M 15.69%
559,381
+91,699
+20% +$7.93M
IMMU
4
DELISTED
Immunomedics Inc
IMMU
$25.9M 9.91%
1,956,362
+17,750
+0.9% +$261K
ASND icon
5
Ascendis Pharma A/S
ASND
$16.4B
$19.7M 7.51%
204,088
– –
MYOK
6
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$15.6M 5.95%
298,666
-15,734
-5% -$837K
AIMT
7
DELISTED
Aimmune Therapeutics
AIMT
$12.8M 4.89%
611,893
-35,361
-5% -$722K
EPZM
8
DELISTED
Epizyme, Inc
EPZM
$10.3M 3.93%
998,278
– –
XLRN
9
DELISTED
Acceleron Pharma
XLRN
$10.1M 3.85%
254,923
– –
NTRA icon
10
Natera
NTRA
$36.4B
$9.4M 3.59%
286,468
– –
BOLD
11
DELISTED
Audentes Therapeutics, Inc
BOLD
$8.86M 3.38%
315,331
– –
REPL icon
12
Replimune Group
REPL
$443M
$7.92M 3.02%
569,662
-209,994
-27% -$2.58M
CBAY
13
DELISTED
Cymabay Therapeutics
CBAY
$7.72M 2.95%
1,508,091
-79,010
-5% -$478K
BHVN
14
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$2.23M 0.85%
53,345
-11,904
-18% -$503K
FBRX icon
15
Forte Biosciences
FBRX
$1.57B
– –
-1,515
Closed -$3.79M
RCUS icon
16
Arcus Biosciences
RCUS
$3.38B
– –
-1,366,973
Closed -$10.9M
WVE icon
17
Wave Life Sciences
WVE
$1.14B
– –
-139,900
Closed -$3.65M
BDSI
18
DELISTED
BioDelivery Sciences International, Inc.
BDSI
– –
-454,656
Closed -$2.11M

Similar funds

PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
KCGDR
Kiron Capital Gestao de Recursos Sao Paulo, Brazil $36.9M AUM 49.85% 1-Year Est. Return
SEM
Spectrum Equity Management San Francisco, California $39.1M AUM 63.69% 1-Year Est. Return
ALFIA
Accel Leaders Fund II Associates Palo Alto, California $36.6M AUM 58.14% 1-Year Est. Return
MCMI
Matrix China Management III Grand Cayman, Cayman Islands $39.3M AUM
LCM
LH Capital Markets New York $39.4M AUM 14.61% 1-Year Est. Return
HLC
Hunt Lane Capital New York $39.6M AUM 58.74% 1-Year Est. Return
KXA
KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return

Foresite Capital Management III's Q3 2019 Portfolio in Review

As of Q3 2019, Foresite Capital Management III held 18 positions worth $262M, down 14% from $305M the previous quarter. Its ten largest holdings account for 90% of the portfolio.

Foresite Capital Management III withdrew a net $14.5M in Q3 2019, closing 4 positions and reducing 6 holdings. Its most notable exit was Arcus Biosciences, an estimated $10.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, up from 68% a quarter earlier.

Against the trend, Foresite Capital Management III added an estimated $9.16M to Aerie Pharmaceuticals.

  • Foresite Capital Management III added most to Aerie Pharmaceuticals in Q3 2019, an estimated $9.16M increase.
  • Foresite Capital Management III's biggest Q3 2019 reduction was Alder Biopharmaceuticals, cutting an estimated $6.27M.
  • Foresite Capital Management III fully exited Arcus Biosciences in Q3 2019, selling an estimated $10.9M.
  • Foresite Capital Management III's ten largest holdings make up 90% of its $262M portfolio in Q3 2019.
  • Foresite Capital Management III opened 0 new positions and closed 4 in Q3 2019.
  • Foresite Capital Management III's portfolio value fell 14% quarter-over-quarter to $262M.

Based on Foresite Capital Management III's 13F filing for Q3 2019, filed 13 Nov 2019.